Clinical Trials Snapshot

Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma

Phase 1, interventional, open-label study to determine the largest safe dose of chimeric T cells for patients with sarcoma, and to determine the safety of providing HER2-CD28 T cells after lymphodepleting chemotherapy.

Phase 1, interventional, open-label study to determine the largest safe dose of chimeric T cells for patients with sarcoma, and to determine the safety of providing HER2-CD28 T cells after lymphodepleting chemotherapy.